The FDA has launched a pilot program to find ways to track medicine supply, such as using blockchain. Technologies like blockchain could track pills, keep them from leaving the supply chain, and provide a way to verify their origin. (Engadget)
Sanofi and Regeneron have cut the list price of their cholesterol drug by 60%. The treatment, Praluent, will cost $5,850 per year, matching the price of Amgen’s rival cholesterol drug. The drugmakers hope the lower price will increase use of Praluent. (Reuters)
The FDA has accused Juul and Altria of breaking promises to curb teen vaping. Altria, the maker of Marlboro, made a $12.8 billion investment in Juul last year. FDA Commissioner Scott Gottlieb has called the CEOs in and again threatened to pull e-cigarettes from the market. (CNBC)
More executive departures are expected at AstraZeneca as the company reorganizes. The company is restructuring its R&D business and absorbing subsidiary MedImmune. Some MedImmune execs have already departed, but more are expected to leave as the reorg continues. (Endpoints)
The FDA is taking action against illegally marketed dietary supplements. The agency is cracking down on supplements that claim to prevent or treat Alzheimer’s, diabetes, and cancer. It sent 12 warning letters to supplement manufacturers over their marketing claims. (CNN)
